Related Experiment Videos
Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer
Abstract:
Mitonafide is the lead compound of a new series of antitumor drugs, the 3-Nitronaphthalimides, which have shown antineoplastic activity in vitro as well as in vivo. This phase I Mitonafide study in non-small cell lung cancer using a 120-hour continuous infusion (120 h. C.I.) schedule of administration was designed to deliver the maximum amount of drug while avoiding the risk of central nervous system (CNS) toxicity, previously observed in studies with daily short (1 hour) administration schedules. Twenty patients were treated at doses ranging from 107-200 mg/m2 x 120 h. C.I. Dose-limiting toxicity with this schedule of administration was leukopenia. Other toxicities were mild or not relevant. No CNS toxicity was observed. The recommended dose for phase II C.I. Mitonafide studies is 170 mg/m2 x 120 h. C.I. in previously untreated patients. Plasma level monitoring is recommended.
Insights
Mitonafide, a novel antitumor drug, was evaluated in a Phase I study for non-small cell lung cancer. A 120-hour continuous infusion schedule minimized CNS toxicity, establishing a recommended dose for future trials.
Area of Science:
- Oncology
- Pharmacology
- Clinical Drug Development
Background:
- Mitonafide is a novel antitumor agent belonging to the 3-Nitronaphthalimide class.
- This drug class exhibits significant antineoplastic activity both in vitro and in vivo.
- Previous administration schedules were associated with central nervous system (CNS) toxicity.
Purpose of the Study:
- To evaluate the safety and tolerability of Mitonafide in patients with non-small cell lung cancer (NSCLC).
- To determine the maximum tolerated dose (MTD) and recommended dose for Phase II studies.
- To assess the efficacy of a 120-hour continuous infusion (120 h. C.I.) schedule in mitigating CNS toxicity.
Main Methods:
- Phase I clinical trial involving 20 patients with NSCLC.
- Administration of Mitonafide using a 120-hour continuous infusion schedule.
- Dose escalation from 107 mg/m2 to 200 mg/m2.
Main Results:
- Leukopenia was identified as the dose-limiting toxicity for the 120 h. C.I. schedule.
- No CNS toxicity was observed with the continuous infusion schedule.
- The recommended dose for Phase II studies was determined to be 170 mg/m2 x 120 h. C.I.
Conclusions:
- The 120-hour continuous infusion schedule of Mitonafide is safe and well-tolerated in NSCLC patients.
- This schedule effectively avoids the CNS toxicity seen with shorter administration durations.
- Plasma level monitoring is advised for future Mitonafide studies.